Welcome to the Hantel Lab

The Hantel Lab leverages health services methods to address ethical dilemmas in cancer discovery and delivery. Specific interests include patient access to and participation in clinical research, the intersection of climate change and cancer health, and the clinical applications of artificial intelligence.

• Dr. Hantel, Dr. Merz, and Dr. Hibb's article, "Cancer Trial Eligibility and Therapy Modifications for Individuals with Duffy Null-Associated Neutrophil Count," was cited in the newly released FDA Guidance, "Cancer Clinical Trial Eligibility Criteria: Laboratory Values Guidance for Industry, IRBs and Clinical Investigators."

   

• Dr. Hantel's article, "Ethical Design and Implementation of Monetary Transfer Interventions in Clinical Cancer Research," was published in the Journal of Clinical Oncology. 

   

• Dr. Blackstone delivered a presentation at the International Conference on Clinical Ethics and Consultation (ICCEC), about his work on the implementation of scarce resource allocation during a large chemotherapy shortage.